JPMorgan Raises Regeneron Pharmaceuticals Price Target to $950

JPMorgan Chase & Co. has raised its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) from $900.00 to $950.00, indicating a potential upside of 29.25% from its current price. The firm maintained an "overweight" rating on the biopharmaceutical company's stock in a note issued to investors on Tuesday.

Several other research analysts have recently updated their ratings and price targets for Regeneron Pharmaceuticals. Guggenheim increased its target from $1,000.00 to $1,030.00 with a "buy" rating, while HSBC raised its target from $800.00 to $920.00 with a "buy" rating. Benchmark upgraded its rating from "hold" to "buy" with a $185.00 target, and Wells Fargo boosted its target from $700.00 to $750.00 with an "equal weight" rating. Piper Sandler slightly reduced its target from $855.00 to $854.00 but kept an "overweight" rating.

According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $813.67. The stock has attracted diverse analyst opinions, with one "Strong Buy" rating, sixteen "Buy" ratings, and nine "Hold" ratings.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up $8.54 during trading hours on Tuesday, hitting $735.01. The company has a 52-week low of $541.00 and a 52-week high of $859.34. Its market capitalization stands at $75.68 billion, with a P/E ratio of 18.10 and a P/E/G ratio of 1.41. The company reported strong quarterly earnings, topping estimates with $14.29 earnings per share and revenue of $4.29 billion.